Deanna Tucker, PharmD

Title: Senior Medical Science Liaison

Organization: Sarepta Therapeutics

Bio: Deanna is a clinical pharmacist by education and has worked in the pharmaceutical industry for over 17 years. She began working with Sarepta Therapeutics is 2019 and serves as the team leader for the Medical Science Liaison team.

2021 FUTURES: Exon Skipping Panel

Information and updates on exon skipping therapies and research from experts in the Duchenne community.

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

See more from same speaker

Kevin Eggan, PhD

Group Vice President, Head of Research and Early Development

BioMarin

See more from same speaker

Leslie Magnus, MD

Vice President, Medical Affairs

NS Pharma

See more from same speaker

James McArthur, PhD

President and Chief Executive Officer

PepGen

See more from same speaker

Lianna Orlando, PhD

Senior Director of Research

CureDuchenne

See more from same speaker

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

2021 FUTURES: Gene Therapy & Gene Editing Symposium

Information and updates on the gene therapy and gene editing landscape from experts in the field.

**We experienced a technical issue during this session. Please reach out with questions to Futures@CureDuchenne.org if needed.

Beth Belluscio, MD, PhD

Global Clinical Lead, Rare Neurological Disorders

Pfizer

See more from same speaker

Olivier Danos, PhD

Chief Scientific Officer

REGENXBIO

See more from same speaker

Emil Kakkis, PhD

CEO & President

Ultragenyx Pharmaceutical

See more from same speaker

Michael Kelly, PhD

Chief Scientific Advisor

CureDuchenne

See more from same speaker

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

See more from same speaker

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

See more from same speaker

Eric Olson, PhD

Chief Scientific Advisor

Vertex Pharmaceuticals

See more from same speaker

Matthew Pletcher, PhD

Division Head of Gene Therapy Research & Technical Operations

Astellas Gene Therapies

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Genine Winslow, MSc

CEO & President

Chameleon Biosciences

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years

Exon Skipping and Read Through Agents Panel

A brief introduction on the rationale behind mechanisms of endogenous dystrophin restoration, like exon skipping and read through agent therapies, followed by critical information and updates from the companies in this space. Moderated discussion included.

Barry Byrne, MD, PhD

Professor and Associate Chair

University of Florida, Department of Pediatrics

See more from same speaker

Jay Chauhan, PharmD

Medical Science Liaison

NS Pharma

See more from same speaker

Brett Crawford, PhD

Executive Director and Head of the Musculoskeletal Therapeutic Area

BioMarin Pharmaceutical Inc.

See more from same speaker

Ash Dugar, PhD

Senior Vice President, Medical Affairs

Dyne Therapeutics

See more from same speaker

Xiao Shelley Hu, PhD, MS

VP

Wave Life Sciences

See more from same speaker

Matthew Klein, M.D., M.S., FACS

Chief Operating Officer

PTC Therapeutics

See more from same speaker

Nerissa Kreher, MD, MBA

Chief Medical Officer

Entrada Therapeutics

See more from same speaker

James McArthur, PhD

President and Chief Executive Officer

PepGen

See more from same speaker

Mark Stahl, MD, PhD

Senior Medical Director, Clinical Development

Avidity Biosciences

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 years

Gene Therapy and Gene Editing Symposium

A brief overview of the strategy guiding efforts in gene therapy and gene editing, as well as critical updates from the companies in this space. Moderated discussion included.

Jeffrey Chamberlain, PhD

Moderators

See more from same speaker

Reed Clark, PhD

Chief Science Officer, Ultragenyx Gene Therapy

Ultragenyx

See more from same speaker

Olivier Danos, PhD

Chief Scientific Officer

REGENXBIO

See more from same speaker

Jennifer Hodge, PhD

Team Lead, Rare Neurology USMA

Pfizer

See more from same speaker

Alison Mcvie-Wylie, PhD

Vice President, Disease Area Executive, DMD

Vertex Pharmaceutical

See more from same speaker

Carl Morris, PhD

Chief Scientific Officer

Solid Biosciences

See more from same speaker

Deanna Tucker, PharmD

Senior Medical Science Liaison

Sarepta Therapeutics

See more from same speaker

Video
Share this:
Beginning the Journey - diagnosed 0-3 yearsGrowth and Transformation - diagnosed 3-6 yearsSpreading Wisdom - diagnosed 6+ years